Discontinued — last reported Q3 '22
Year-over-year, this metric grew by 1500.0%, from $5.00M to $80.00M. Over 4 years (FY 2021 to FY 2025), Acquisitions shows a downward trend with a -24.6% CAGR.
High spending indicates an aggressive growth strategy, while low spending may indicate a focus on organic growth or debt reduction.
This represents the net cash outflow for the purchase of other businesses or strategic assets, adjusted for any cash acq...
Highly variable; pharmaceutical companies frequently use M&A to offset patent cliffs and expand therapeutic portfolios.
cf_acquisitions| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $8.50M | $0.00 | -$349.00M | $1.73B | $0.00 | $2.00M | $74.00M | $638.00M | $51.00M | $0.00 | $0.00 | $21.00M | $0.00 | $6.00M | $0.00 | $5.00M | $0.00 | $5.00M | $0.00 | $80.00M |
| QoQ Change | — | -100.0% | — | +595.7% | -100.0% | — | >999% | +762.2% | -92.0% | -100.0% | — | — | -100.0% | — | -100.0% | — | -100.0% | — | -100.0% | — |
| YoY Change | — | — | — | — | -100.0% | — | +121.2% | -63.1% | — | -100.0% | -100.0% | -96.7% | -100.0% | — | — | -76.2% | — | -16.7% | — | >999% |
We use cookies for analytics. See our Privacy and Cookie Policy.